The incidence of adverse events is not correlated with age; however, adverse events occur more often in females than in males.<ref name="pmid7593736">{{cite journal |vauthors=Guentert TW, Banken L, Hilton S, Holford NH |title=Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events |journal=J Clin Psychopharmacol |volume=15 |issue=4 Suppl 2 |pages=84S–94S |date=August 1995 |pmid=7593736 |doi=10.1097/00004714-199508001-00014}}</ref> Moclobemide is regarded as a generally safe antidepressant and due to its favorable side effect profile, it can be considered a first-line therapeutic antidepressant.<ref name="pmid7622819">{{cite journal |vauthors=Swinkels JA, de Jonghe F |title=Safety of antidepressants |journal=Int Clin Psychopharmacol |volume=9 Suppl 4 |issue= |pages=19–25 |date=January 1995 |pmid=7622819 |doi=10.1097/00004850-199501004-00003}}</ref> Side effects of moclobemide are exceptionally low,<ref name="pmid1609337">{{cite journal |vauthors=Priest RG, Baldwin DS, Bullock T, Kibel D, Smeyatsky N, Steinert J |title=Recent advances in antidepressant drugs |journal=S. Afr. Med. J. |volume=Suppl |issue= |pages=1–4 |date=June 1992 |pmid=1609337 }}</ref> with [[insomnia]], headache and dizziness being the most commonly reported side effects in the initial stages of therapy with moclobemide.<ref name="pmid7954486">{{cite journal |vauthors=Moll E, Neumann N, Schmid-Burgk W, Stabl M, Amrein R |title=Safety and efficacy during long-term treatment with moclobemide |journal=Clin Neuropharmacol |volume=17 Suppl 1 |issue= |pages=S74–87 |year=1994 |pmid=7954486 |doi=10.1097/00002826-199417001-00009}}</ref> Many antidepressants have an adverse effect on sexual function; however, treatment with moclobemide has actually been found to improve sexual function.<ref name="pmid8144126">{{cite journal |vauthors=Baier D, Philipp M |title=[Modification of sexual functions by antidepressants] |language=German |journal=Fortschr Neurol Psychiatr |volume=62 |issue=1 |pages=14–21 |date=January 1994 |pmid=8144126 |doi=10.1055/s-2007-996652 }}</ref> Moclobemide does not have any adverse effect on cognitive abilities, thus there are no impairments of moclobemide therapy on memory, attention functions nor is ability to drive a motor vehicle affected adversely.<ref name="pmid8174512">{{cite journal |vauthors=Amado-Boccara I, Gougoulis N, Poirier-Littré MF, Galinowski A, Lôo H |title=[Effects of antidepressants on cognitive functions. Review of the literature] |language=French |journal=Encephale |volume=20 |issue=1 |pages=65–77 |year=1994 |pmid=8174512 }}</ref> In fact, moclobemide has been found to improve cognition, especially memory{{citation needed|date=December 2015}}; this is relevant with regard to the elderly as adverse effects on cognition are of particular concern in this population. People with dementia and [[comorbid]] depression also show improvements in cognitive impairments; these improvements are unrelated to alleviation of depression{{citation needed|date=December 2015}}. Alcohol related cognitive impairments are also improved by moclobemide{{citation needed|date=December 2015}}. Improvements in cognition also occur in young depressed people after 6 weeks of treatment{{citation needed|date=December 2015}}. There is a mild impairment in psychometric performance in elderly people but none in younger people{{citation needed|date=December 2015}}. Moclobemide, even at high doses of 600&nbsp;mg, does not impair the ability to drive a motor vehicle.<ref name="pmid7905288"/><ref name="pmid1377119"/> The tolerability of moclobemide is similar in women and men and it is also well tolerated in the elderly.<ref name="pmid2123366">{{cite journal |vauthors=Versiani M, Nardi AE, Figueira IL, Stabl M |title=Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo |journal=Acta Psychiatr Scand Suppl |volume=360 |issue= |pages=24–8 |year=1990 |pmid=2123366 }}</ref> Moclobemide is tolerated to a similar degree to the SSRI antidepressants, although unlike SSRIs moclobemide does not cause sexual dysfunction and gastrointestinal disturbance is less common{{citation needed|date=December 2015}}. Moclobemide has been found to be superior to tricyclic and irreversible MAOI antidepressants in terms of side effects, as it does not cause [[anticholinergic]], sedative or cardiovascular adverse effects<ref name="pmid8875133"/> as well as not causing weight gain.<ref name="pmid1377119">{{cite journal |vauthors=Fitton A, Faulds D, Goa KL |title=Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness |journal=Drugs |volume=43 |issue=4 |pages=561–96 |date=April 1992 |pmid=1377119 |doi=10.2165/00003495-199243040-00009}}</ref>

 


 
Unlike the irreversible MAOIs there is no evidence of liver toxicity with moclobemide.<ref name="pmid1394030">{{cite journal |vauthors=Amrein R, Hetzel W, Stabl M, Schmid-Burgk W |title=RIMA: a safe concept in the treatment of depression with moclobemide |journal=Can J Psychiatry |volume=37 Suppl 1 |issue= |pages=7–11 |date=September 1992 |pmid=1394030 }}</ref> Moclobemide has a similar efficacy profile compared to other antidepressants but is significantly superior to the tricyclic antidepressants and the classic (unselective or irreversible) MAOIs, in terms of tolerance and safety profile.<ref name="pmid7741983">{{cite journal |vauthors=Norman TR, Burrows GD |title=A risk-benefit assessment of moclobemide in the treatment of depressive disorders |journal=Drug Saf |volume=12 |issue=1 |pages=46–54 |date=January 1995 |pmid=7741983 |doi=10.2165/00002018-199512010-00004}}</ref> Moclobemide has little effect on [[Psychomotor learning|psychomotor]] functions.<ref name="pmid2248062"/> Other side effects include, nausea, insomnia, tremor and lightheadedness; [[orthostatic hypotension]] (dizziness upon standing) is uncommon even among the elderly.<ref name="pmid10063483"/> Behavioural toxicity or other impairments relating to everyday living does not occur with moclobemide, except in doses of 400&nbsp;mg or higher, peripheral reaction time may be impaired.<ref name="pmid1546141">{{cite journal |vauthors=Hindmarch I, Kerr J |title=Behavioural toxicity of antidepressants with particular reference to moclobemide |journal=Psychopharmacology |volume=106 Suppl |issue= |pages=S49–55 |year=1992 |pmid=1546141 |doi=10.1007/bf02246236}}</ref> [[Peripheral oedema]] has been associated with moclobemide.<ref name="pmid1630391">{{cite journal |vauthors=Alderman CP, Callary JA, Kent AL |title=Peripheral oedema associated with moclobemide |journal=Med. J. Aust. |volume=157 |issue=2 |pages=144 |date=July 1992 |pmid=1630391 }}</ref>

 


 
Most of the side effects are transient disappearing within 2 weeks of treatment.<ref name="pmid7593727">{{cite journal |vauthors=Tiller JW, Johnson GF, Burrows GD |title=Moclobemide for depression: an Australian psychiatric practice study |journal=J Clin Psychopharmacol |volume=15 |issue=4 Suppl 2 |pages=31S–34S |date=August 1995 |pmid=7593727 |doi=10.1097/00004714-199508001-00006}}</ref> [[Fatigue (medical)|serious fatigue]], headache, restlessness, nervousness and sleep disturbances have been described as side effects from moclobemide therapy.<ref name="Rimón-1993">{{Cite journal  | last1 = Rimón | first1 = R. | last2 = Jääskeläinen | first2 = J. | last3 = Kaartinen | first3 = P. | last4 = Kalli | first4 = A. | last5 = Kilponen | first5 = E. | last6 = Koskinen | first6 = T. | last7 = Nikkilä | first7 = H. | last8 = Pirttiperä | first8 = V. | last9 = Seppälä | first9 = J. | title = Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study | journal = Int Clin Psychopharmacol | volume = 7 | issue = 3–4 | pages = 141–7 |date=Jan 1993 | pmid = 8468435 | doi=10.1097/00004850-199300730-00004 }}</ref> A [[paradoxical effect|paradoxical]] worsening of depression has been reported in some individuals in several studies,<ref name="pmid8354766">{{cite journal |title=Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group |journal=J Affect Disord |volume=28 |issue=2 |pages=105–16 |date=June 1993 |pmid=8354766 |doi=10.1016/0165-0327(93)90039-M}}</ref> and reports of suicidal ideation and suicide as an adverse effect have been reported as a rare adverse effect of moclobemide.<ref name="pmid7941097">{{cite journal |author=Gram LF |title=[Antidepressive drug therapy, suicidal ideation and suicide, 2 cases reported in connection with moclobemide (Aurorix) therapy] |language=Danish |journal=Ugeskrift for Læger |volume=156 |issue=38 |pages=5542 |date=September 1994 |pmid=7941097 }}</ref> Overall, antidepressants decrease the risk of suicide.<ref name="pmid9272192">{{cite journal |vauthors=Isacsson G, Holmgren P, Druid H, Bergman U |title=The utilization of antidepressants--a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994 |journal=Acta Psychiatr Scand |volume=96 |issue=2 |pages=94–100 |date=August 1997 |pmid=9272192 |doi=10.1111/j.1600-0447.1997.tb09912.x}}</ref> Moclobemide is believed to have only small proconvulsant effects;<ref name="pmid9512919">{{cite journal |vauthors=Curran S, de Pauw K |title=Selecting an antidepressant for use in a patient with epilepsy. Safety considerations |journal=Drug Saf |volume=18 |issue=2 |pages=125–33 |date=February 1998 |pmid=9512919 |doi=10.2165/00002018-199818020-00004}}</ref> however, rarely seizures may occur.<ref name="pmid7954487">{{cite journal |vauthors=Bisserbe JC, Lépine JP |title=Moclobemide in social phobia: a pilot open study. GRP Group. Groupe de Recherche en Psychopharmacologie |journal=Clin Neuropharmacol |volume=17 Suppl 1 |issue= |pages=S88–94 |year=1994 |pmid=7954487 |doi=10.1097/00002826-199417001-00010}}</ref> [[Hypertension]], has been reported to occur very rarely with moclobemide therapy.<ref name="pmid10063483"/>

 


 
Moclobemide is relatively well tolerated. The following are the potential adverse effects and their respective incidences:<ref name=SANDOZ>{{cite web|title=PRODUCT INFORMATION MOCLOBEMIDE SANDOZ® 150mg and 300mg TABLETS|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01146-3|work=TGA eBusiness Services|publisher=Sandoz|accessdate=16 October 2013|date=6 March 2012}}</ref><ref name=AURORIX>{{cite web|title=NAME OF THE DRUG AURORIX|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04017-3|work=TGA eBusiness Services|publisher=Meda Valeant Pharma Australia Pty Limited|accessdate=16 October 2013|date=7 January 2013}}</ref>

 


 
;Common (>1% incidence) adverse effects

 
* Nausea

 
* Dry mouth

 
* Constipation

 
* Diarrhoea

 
* Insomnia

 
* Dizziness

 
* Anxiety

 
* Restlessness

 


 
;Uncommon/Rare (<1%) adverse effects

 
{{div col|4}}

 
* Difficulties falling asleep

 
* Nightmares/dreams

 
* Hallucinations

 
* Memory disturbances, 

 
* Confusion

 
* Disorientation

 
* Delusions

 
* Increased depression

 
* Excitation/irritability

 
* Hypomania 

 
* Mania

 
* Aggressive behaviour

 
* Apathy

 
* Tension

 
* Suicidal ideation

 
* Suicidal behaviour

 
* Migraine

 
* Extrapyramidal effects

 
* Tinnitus

 
* Paraesthesia 

 
* Dysarthria

 
* Heartburn

 
* Gastritis

 
* Meteorism

 
* Indigestion

 
* Hypertension

 
* Bradycardia

 
* Extrasystoles

 
* Angina/chest pain

 
* Phlebetic symptoms

 
* Flushing

 
* Exanthema/rash

 
* Allergic skin reaction

 
* Itching

 
* Gingivitis

 
* Stomatitis

 
* Dry skin

 
* Conjunctivitis

 
* Pruritus

 
* Urticaria

 
* Disturbances of micturition (dysuria, polyuria, tenesmus)

 
* Metrorrhagia

 
* Prolonged menstruation

 
* General malaise

 
* Skeletal/muscular pain

 
* Altered taste sensations

 
* Hot flushes/cold sensation

 
* Photopsia

 
* Dyspnoea

 
* Visual disturbances

 
* Increased hepatic enzymes without associated clinical sequelae.

 
{{div col end}}

 

